1. Miller, R. M., Happe, L. E., Meyer, K. L., & Spear, R. J. (2012). Approaches to the management of agents used for the treatment of multiple sclerosis: consensus statements from a panel of US managed care pharmacists and physicians. Journal of Managed Care Pharmacy, 18(1), 54–62.
2. Sturm, D., Gurevitz, S. L., & Turner, A. (2014). Multiple sclerosis: a review of the disease and treatment options. The Consultant Pharmacist®, 29(7), 469–479.
3. Goodin, D. S., Frohman, E. M., Garmany, G. P., Halper, J., Likosky, W. H., & Lublin, F. D. (2002). Disease modifying therapies in multiple sclerosis. Neurology, 58(2), 169–78.
4. Tullman, M. J. (2013). Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manag Care, 19(2 Suppl), S15–20.
5. Navidinia, M., Gholinejad, K., Derakhshan, S., Rahimipour, A., Kazerouni, F., & Sahraian, M. A. (2018). The epidemiology of microbial agents related to patients with multiple sclerosis (MS). Archives of Advances in Biosciences, 9(3), 9–15.